Alternative designs for clinical trials in rare diseases, American Journal of Medical Genetics Part C : Seminars in Medical Genetics, vol.172, issue.4, p.43, 2016. ,
Survival distributions impact the power of randomized placebophase design and parallel groups randomized clinical trials, Journal of Clinical Epidemiology, vol.64, issue.3, p.34, 2011. ,
Combining expert opinions in prior elicitation, Bayesian Analysis, vol.7, issue.3, p.57, 2012. ,
Bayesian Methods in Risk Assessment, Advances in Nuclear Science and Technology, pp.415-465, 1981. ,
Biomarkers and surrogate endpoints, British Journal of Clinical Pharmacology, vol.59, issue.5, p.44, 2005. ,
Methods for Expert-Opinion Elicitation of Probabilities and Consequences for Corps Facilities, vol.57, p.101, 2000. ,
Prior information and subjective probability, Statistical Decision Theory and Bayesian Analysis, vol.66, p.63, 1985. ,
DOI : 10.1007/978-1-4757-1727-3_3
N-of-1 clinical trials should be incorporated into clinical practice, Journal of Clinical Epidemiology, vol.63, issue.12, p.43, 2006. ,
Small sample sizes in clinical trials : a statistician's perspective, Clinical Investigation, vol.2, issue.7, pp.79-80, 2012. ,
DOI : 10.4155/cli.12.62
Subgroup analyses in randomised controlled trials : quantifying the risks of false-positives and false-negatives. Health Technology Assessment, vol.5, p.43, 2001. ,
Evidence for use of coronary stents. a hierarchical bayesian meta-analysis, Annals of Internal Medicine, vol.138, issue.10, pp.777-786, 2003. ,
Priority vector and consistency, Introduction to the Analytic Hierarchy Process, SpringerBriefs in Operations Research, pp.17-31, 2015. ,
DOI : 10.1007/978-3-319-12502-2_2
, , vol.88, p.97
Clinical trials of orphan medicines, The Lancet, vol.371, issue.9629, pp.51-77, 2008. ,
DOI : 10.1016/s0140-6736(08)60876-4
Helping doctors to draw appropriate inferences from the analysis of medical studies, Statistics in Medicine, vol.13, issue.17, p.80, 1994. ,
Prednisone plus methotrexate for polymyalgia rheumatica : a randomized, double-blind, placebo-controlled trial, Annals of Internal Medicine, vol.141, issue.7, p.145, 2004. ,
DOI : 10.7326/0003-4819-141-7-200410050-00005
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders, American journal of epidemiology, vol.158, issue.3, p.45, 2003. ,
Quantifying and documenting prior beliefs in clinical trials, Statistics in medicine, vol.20, issue.4, p.110, 2001. ,
, Bibliographie 179
Elicitation by design in ecology : using expert opinion to inform priors for bayesian statistical models, Ecology, vol.90, issue.1, p.99, 2009. ,
Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed ? Movement Disorders, vol.23, p.24, 2008. ,
Reducing selection bias in case-control studies from rare disease registries, Orphanet Journal of Rare Diseases, vol.6, pp.61-105, 2011. ,
Experts in Uncertainty : Opinion and Subjective Probability in Science, vol.2, pp.102-103, 1991. ,
Experimental designs for small randomised clinical trials : an algorithm for choice, Orphanet Journal of Rare Diseases, vol.8, p.31, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00818031
The geometric mean procedure for estimating the scale of a judgement matrix, Mathematical Modelling, vol.9, issue.3, p.88, 1987. ,
The delayed start study design, New England Journal of Medicine, vol.361, issue.13, pp.25-26, 2009. ,
Bayesian approaches to clinical trials and health-care evaluation, vol.3, p.81, 2003. ,
Why "underpowered" trials are not necessarily unethical, Lancet, vol.350, issue.9080, p.45, 1997. ,
DOI : 10.1016/s0140-6736(97)02290-3
, Efficiency of plasma exchange in Guillain-Barré syndrome : role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome, Annals of Neurology, vol.22, issue.6, p.73, 1987.
Forcing a sequential experiment to be balanced, Biometrika, vol.58, issue.3, p.39, 1971. ,
The role of plasmapheresis in childhood Guillain-Barré syndrome, Annals of Neurology, vol.28, issue.1, p.74, 1990. ,
The randomized placebo-phase design for clinical trials, Journal of Clinical Epidemiology, vol.54, issue.6, p.33, 2001. ,
Biomarkers and surrogate endpoints in clinical trials, Statistics in Medicine, vol.31, issue.25, p.44, 2012. ,
The performance of the two-stage analysis of two-treatment, two-period crossover trials, Statistics in Medicine, vol.8, issue.12, p.27, 1989. ,
A literature review on the use of expert opinion in probabilistic risk analysis, pp.102-103, 2004. ,
Innovative research methods for studying treatments for rare diseases : methodological review, BMJ, vol.349, pp.6802-6847, 2014. ,
The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results, New England Journal of Medicine, vol.348, issue.24, pp.200-245, 1994. ,
A bayesian approach to randomized controlled trials in children utilizing information from adults : the case of Guillain-Barre, Clinical Trials, vol.2, issue.4, p.81, 2005. ,
Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care, Neurology, vol.52, issue.7, pp.1494-1497, 1999. ,
Using prior distributions to synthesize historical evidence : comments on the Goodman-Sladky case study IVIg in Guillain-Barré syndrome, Clinical Trials, vol.2, issue.4, p.47, 2005. ,
Clinical research for rare disease : Opportunities, challenges, and solutions. Molecular genetics and metabolism, vol.96, pp.26-31, 2009. ,
Using historical control information for the design and analysis of clinical trials with overdispersed count data, Statistics in Medicine, vol.32, issue.21, pp.3609-3622, 2013. ,
A framework for applying unfamiliar trial designs in studies of rare diseases, Journal of Clinical Epidemiology, vol.64, issue.10, pp.26-27, 2011. ,
The continuing unethical conduct of underpowered clinical trials, JAMA, vol.288, issue.3, p.46, 2002. ,
Bayesian methods for the design and interpretation of clinical trials in very rare diseases, Statistics in Medicine, vol.33, issue.24, p.115, 2014. ,
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis, and International Network for the Study of Systemic Vasculitides, vol.46, pp.1309-1318, 2002. ,
The Theory of Response-Adaptive Randomization in Clinical Trials, GoogleBooks-ID : CmkFQ2Qibk8C. 2 citations pages, pp.36-37, 2006. ,
Reporting Bayesian analyses of clinical trials, Statistics in Medicine, vol.12, issue.18, p.80, 1993. ,
Analytic hierarchy process and expert choice : Benefits and limitations, OR Insight, vol.22, issue.4, p.97, 2009. ,
Guillain-Barré syndrome in childhood : natural course and efficacy of plasmapheresis, Pediatric Neurology, vol.9, issue.1, pp.16-20, 1993. ,
Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (ssc-pah) and idiopathic pah. belief elicitation for bayesian priors, The Journal of rheumatology, vol.38, issue.3, p.110, 2011. ,
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial, The Clinical Journal of Pain, vol.134, issue.2, p.32, 2001. ,
Plasmapheresis with acute inflammatory polyneuropathy, Pediatric Neurology, vol.6, issue.1, pp.17-19, 1990. ,
The overemphasis on power analysis. Nursing Research, vol.45, p.45, 1996. ,
A new definition of consistency of pairwise comparisons, Mathematical and Computer Modelling, vol.18, issue.7, p.94, 1993. ,
Natural history and treatment effects in Guillain-Barré syndrome : a multicentre study, Archives of Disease in Childhood, vol.74, issue.4, pp.281-287, 1996. ,
Clinical trials and rare diseases, The New England Journal of Medicine, vol.348, issue.24, p.26, 2003. ,
Plasmapheresis in children with Guillain-Barré syndrome, Neurology, vol.41, issue.12, p.74, 1991. ,
Clinical trials and rare diseases : a way out of a conundrum, Bmj, vol.311, issue.7020, p.79, 1995. ,
The n-of-1 clinical trial : the ultimate strategy for individualizing medicine ? Personalized medicine, vol.8, p.30, 2011. ,
Delayed-start analysis : Mild alzheimer's disease patients in solanezumab trials, 3.5 years, Alzheimer's & Dementia : Translational Research & Clinical Interventions, vol.1, issue.2, pp.24-25, 2015. ,
The case-crossover design : a method for studying transient effects on the risk of acute events, American Journal of Epidemiology, vol.133, issue.2, pp.26-27, 1991. ,
Adaptive design clinical trials : Methodology, challenges and prospect, Indian Journal of Pharmacology, vol.42, issue.4, p.35, 2010. ,
Observational research methods. research design ii : cohort, cross sectional, and case-control studies, Emergency Medicine Journal, vol.20, issue.1, p.26, 2003. ,
Special study designs : early escape, enrichment, studies in non-responders, Communications in Statistics-Theory and Methods, vol.23, issue.2, p.33, 1994. ,
and MÃÂ 1 4 ller, 2008. ,
Design and analysis of crossover trials for absorbing binary endpoints, Clinical Trials, vol.64, issue.2, pp.72-118, 2010. ,
A methodological framework for drug development in rare diseases, Orphanet Journal of Rare Diseases, vol.9, p.31, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01097224
, Uncertain judgements : Eliciting experts probabilities. 4 citations pages, vol.102, p.105, 2006.
A double184 Bibliographie blind, delayed-start trial of rasagiline in parkinson's disease, New England Journal of Medicine, vol.361, issue.13, pp.1268-1278, 2009. ,
Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome : a reappraisal, Annals of Neurology, vol.46, issue.5, pp.701-707, 1999. ,
, Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, Cité page 26 [Plasma, 1997] Plasma, vol.61, p.73, 1997.
, Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group, Neurology, vol.35, issue.8, p.73, 1985.
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, vol.31, issue.1, p.40, 1975. ,
An experiment on the numerical modelling of verbal ratio statements, Journal of Multi-Criteria Decision Analysis, vol.6, issue.1, p.95, 1997. ,
Bayesian sample size determination for estimating binomial parameters from data subject to misclassification, Journal of the Royal Statistical Society : Series C (Applied Statistics), vol.49, issue.1, p.85, 2000. ,
The Bayesian Choice. Springer Texts in Statistics, vol.3, p.66, 2007. ,
The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, p.45, 1983. ,
Randomization in clinical trials : Theory and practice, p.38, 2016. ,
The analytic hierarchy process-what it is and how it is used, Mathematical Modelling, vol.9, issue.3, p.98, 1987. ,
, Bibliographie 185
A scaling method for priorities in hierarchical structures, Journal of Mathematical Psychology, vol.15, issue.3, p.93, 1977. ,
Ranking by eigenvector versus other methods in the analytic hierarchy process, Applied Mathematics Letters, vol.11, issue.4, p.87, 1998. ,
Comparison of eigenvalue, logarithmic least squares and least squares methods in estimating ratios, Mathematical Modelling, vol.5, issue.5, pp.87-93, 1984. ,
A Comparison of the Bayesian and Frequentist Approaches to Estimation, Springer Science & Business Media. Google-Books-ID : WGaKMfKm0sAC. Cité page, p.53, 2010. ,
Solution of the least squares method problem of pairwise comparison matrices, Central European Journal of Operations Research, vol.16, issue.4, 2008. ,
The network meta-analytic-predictive approach to non-inferiority trials, Statistical Methods in Medical Research, vol.22, issue.2, pp.219-240, 2013. ,
Cross-over trials in statistics in medicine : the first 25 years, Statistics in Medicine, vol.25, issue.20, p.27, 2006. ,
The randomized placebo-phase design : Evaluation, interim monitoring and analysis, p.34, 2010. ,
Prospective meta-analysis of cholesterol-lowering studies : the prospectivepravastatin pooling (ppp) project and the cholesterol treatment trialists (ctt) collaboration, The American Journal of Cardiology, vol.76, issue.9, p.45, 1995. ,
A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA), Clinical and Experimental Rheumatology, vol.19, issue.5, p.133, 2001. ,
Enriched enrolment : definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review, British Journal of Clinical Pharmacology, vol.66, issue.2, p.32, 2008. ,
Retrospective outcomes studies for orphan diseases : challenges and opportunities, Current Medical Research & Opinion, vol.28, issue.4, p.44, 2012. ,
Inverse sensitive analysis of pairwise comparison matrices, Journal of the Operations Research Society of Japan, vol.49, issue.4, p.94, 2006. ,
Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, issue.7405, p.80, 2003. ,
Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, issue.7405, p.72, 2003. ,
Can external and subjective information ever be used to reduce the size of randomised controlled trials ?, Contemporary Clinical Trials, vol.29, issue.2, p.85, 1927. ,
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group, vol.326, p.73, 1992. ,
The adaptive biased coin design for sequential experiments, The Annals of Statistics, vol.6, issue.1, p.39, 1978. ,
K-treatment comparisons with restricted randomization rules in clinical trials, The Annals of Statistics, vol.14, issue.1, p.39, 1986. ,
On the proper use of the crossover design in clinical trials, Deutsches Arzteblatt International, vol.109, issue.15, pp.27-28, 2012. ,
Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates : Methodologic considerations, Journal of clinical epidemiology, vol.63, issue.12, p.30, 2010. ,